Lydus Medical’s Vesseal Device Receives the US FDA’s Clearance for Small Arteries
Shots:
- Lydus Medical, a portfolio company of Sanara Ventures, a joint venture of Teva and Philips received the US FDA 510(k) clearance for its Vesseal, an automated microvascular suturing device delivering thread-only standardized Omni-vessel anastomoses. It is designed to enable simple, fast, easy, safe & effective procedures
- The device delivers simple accurate, dependable & consistent results through the symmetrical placement of 8 micro-sutures at the anastomosis site
- It will be commercially available in the US in Jan 2023 via select distributing partners to support surgeons & patients. The company’s goal is to develop novel medical device products for small blood vessel anastomoses
Ref: PRNewswire | Image: Lydus Medical
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
